Biobanking Upper Gastrointestinal Tumors to Evaluate Response (BURGER With BACON) (NCT06283238) | Clinical Trial Compass
WithdrawnNot Applicable
Biobanking Upper Gastrointestinal Tumors to Evaluate Response (BURGER With BACON)
Stopped: Study abandoned and not opening for recruitment.
United States0Started 2025-04-16
Plain-language summary
The goal of this observational study is to examine genetic changes that may contribute to immunotherapy resistance in gastroesophageal cancer. This information can potentially lead to the identification of new immunotherapeutic targets as well as improve the ability to identify those patients more likely to respond to immunotherapy.
This study does not include any treatment or investigational drugs.
Participants will be asked:
* to enroll before beginning standard care of treatment for their cancer
* for blood, archived tumor tissue, and fresh tumor tissue Researchers will compare participants who are not getting immunotherapy to identify potential differences in expression levels of a gene.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Age \> 18 years
✓. Ability to understand and the willingness to sign a written informed consent document
✓. Diagnosis of gastric, esophageal, or gastroesophageal junction adenocarcinoma or squamous cell carcinoma.
✓. Available archival tumor tissue or willingness to undergo research biopsy.
Exclusion criteria
✕. Patients unable to comply with the requirements of the study protocol
✕. Patients known to be pregnant or nursing
✕. Serious pre-existing medical condition, that in the opinion of the investigator, makes the patient unsuitable for the study
✕. GE subjects must have been treated with an immune checkpoint inhibitor for gastroesophageal adenocarcinoma or squamous cell carcinoma, or have been ineligible for immunotherapy due to low PD-L1 and received chemotherapy.
✕. Melanoma subjects in cohort C must have stage II, III, or IV disease validated by histology or cytology
What they're measuring
1
Number of participants with Complete Response (CR)